MAGELLAN LONGEVITY
HomeResearchStudy library › A randomized controlled trial comparing myoinositol with metformin…
Study summary · General aging biology & healthspan

Does a combination of metformin with myoinositol and d-chiro-inositol offer superior benefits compared to metformin monotherapy in women with PCOS?

In one paragraph

Myo-Inositol, a randomized controlled trial (Clin Endocrinol (Oxf) 2023, PMID 37265016) — menstrual cycle regularity improved in both groups, with significantly greater improvement in the myoinositol combination group (p <.001). Adding myoinositol to metformin improves menstrual regularity and quality of life in women with PCOS more than metformin alone, but other hormonal and metabolic markers are not significantly different.

Source: Clin Endocrinol (Oxf) 2023, PMID 37265016 ↗ · Research map · How Magellan grades evidence · evidence confidence: high

Clin Endocrinol (Oxf) · 2023 · PMID 37265016 · DOI 10.1111/cen.14931

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Adding myoinositol to metformin improves menstrual regularity and quality of life in women with PCOS more than metformin alone, but other hormonal and metabolic markers are not significantly different.

The question

Does a combination of metformin with myoinositol and d-chiro-inositol offer superior benefits compared to metformin monotherapy in women with PCOS?

What they tested

The study implicitly hypothesizes that the combination therapy will exert more beneficial effects in PCOS due to the insulin-sensitizing properties of myoinositol and d-chiro-inositol.

How they did it

This was a 6-month randomized controlled trial involving overweight and obese women with PCOS aged 18-35. Participants were randomized into two groups: 27 received metformin monotherapy, and 26 received metformin with myoinositol and d-chiro-inositol. Various parameters including menstrual cycle duration, anthropometric measures, hormonal profiles, metabolic markers, and quality of life scores were assessed at baseline and after 6 months.

What they found

Menstrual cycle regularity improved in both groups, with significantly greater improvement in the myoinositol combination group (p < .001). The PCOS Questionnaire (PCOSQ) score also showed significant improvement in the myoinositol-based therapy group (p < .001). Pregnancy rates were similar between both groups, and no statistically significant differences were observed in other hormonal or metabolic parameters.

Improvement in Menstrual Cycle Regularity and PCOSQ Score
Values shown: Significant Improvement (1=Yes)
Menstrual Cycle Regularity (Myoinositol group)1
PCOSQ Score (Myoinositol group)1

The chart illustrates that the myoinositol combination group showed significant improvement in menstrual cycle regularity and PCOSQ score compared to the metformin monotherapy group. A value of 1 indicates significant improvement (p < .001).

What it means

Adding myoinositol to metformin provides additional benefits in improving menstrual cycle regularity and quality of life for women with PCOS.

Limitations

The abstract does not explicitly state limitations of the study.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“myoinositol acts as an insulin sensitizer and exerts beneficial effects in PCOS”— from the published abstract, Clin Endocrinol (Oxf) 2023

The paper at a glance

TitleA randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in PCOS
JournalClin Endocrinol (Oxf)
Year2023
PMID37265016 ↗
DOI10.1111/cen.14931 ↗
TopicGeneral aging biology & healthspan

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Myo-Inositol

In randomized trials and meta-analyses, myo-inositol (often combined with D-chiro-inositol) has been associated with improved insulin sensitivity—lower fasting insulin and HOMA-IR—restoration of menstrual regularity and ovulation in PCOS, and a reduced incidence of gestational diabetes (a Cochrane review found…

Myo-Inositol

Myo-inositol is a naturally occurring sugar-like compound (a cyclitol, the most abundant of nine…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Does a combination of metformin with myoinositol and d-chiro-inositol offer superior benefits compared to metformin monotherapy in women with PCOS? [Plain-English summary of Clin Endocrinol (Oxf) 2023, PMID 37265016, DOI 10.1111/cen.14931]. Magellan Longevity. https://magellanlongevity.com/study/d37265016.html
BibTeX
@misc{magellan_d37265016, title = {Does a combination of metformin with myoinositol and d-chiro-inositol offer superior benefits compared to metformin monotherapy in women with PCOS?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d37265016.html}}, note = {Plain-English summary of PubMed PMID 37265016; DOI 10.1111/cen.14931; Clin Endocrinol (Oxf) 2023. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d37265016.html

Related studies in the Magellan library

All 25 Magellan summaries on general aging biology & healthspan →

How this summary was made. Every section above restates what the published abstract of PMID 37265016 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.